JP2005533110A5 - - Google Patents

Download PDF

Info

Publication number
JP2005533110A5
JP2005533110A5 JP2004521686A JP2004521686A JP2005533110A5 JP 2005533110 A5 JP2005533110 A5 JP 2005533110A5 JP 2004521686 A JP2004521686 A JP 2004521686A JP 2004521686 A JP2004521686 A JP 2004521686A JP 2005533110 A5 JP2005533110 A5 JP 2005533110A5
Authority
JP
Japan
Prior art keywords
tetracycline
cmt
pharmaceutical composition
antibacterial
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2004521686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005533110A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/021740 external-priority patent/WO2004006938A1/en
Publication of JP2005533110A publication Critical patent/JP2005533110A/ja
Publication of JP2005533110A5 publication Critical patent/JP2005533110A5/ja
Abandoned legal-status Critical Current

Links

JP2004521686A 2002-07-12 2003-07-11 非抗菌性テトラサイクリン製剤によるc−反応性タンパク質レベルの減少方法 Abandoned JP2005533110A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39546602P 2002-07-12 2002-07-12
PCT/US2003/021740 WO2004006938A1 (en) 2002-07-12 2003-07-11 Method for reducing c-rective protein levels with non-antibacterial tetracycline formulations

Publications (2)

Publication Number Publication Date
JP2005533110A JP2005533110A (ja) 2005-11-04
JP2005533110A5 true JP2005533110A5 (enExample) 2006-10-12

Family

ID=30115878

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004521686A Abandoned JP2005533110A (ja) 2002-07-12 2003-07-11 非抗菌性テトラサイクリン製剤によるc−反応性タンパク質レベルの減少方法

Country Status (8)

Country Link
US (1) US20050282786A1 (enExample)
EP (1) EP1531830A4 (enExample)
JP (1) JP2005533110A (enExample)
KR (1) KR20050034713A (enExample)
AU (1) AU2003256496A1 (enExample)
CA (1) CA2491655A1 (enExample)
NZ (1) NZ538198A (enExample)
WO (1) WO2004006938A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2521885C (en) * 2003-04-07 2013-06-25 Shire Laboratories, Inc. Once daily formulations of tetracyclines
CN105010359B (zh) * 2015-06-24 2018-05-18 广东中迅农科股份有限公司 含有四霉素和氟环唑的杀菌组合物
CN104957154B (zh) * 2015-06-24 2018-05-18 广东中迅农科股份有限公司 含有四霉素和醚菌酯的杀菌组合物
MX2021015266A (es) * 2019-06-14 2022-01-18 Joshua O Atiba Composicion farmaceutica triple para infecciones proteinaceas.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666897A (en) * 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
US5223248A (en) * 1991-02-11 1993-06-29 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing antiplaque properties
US5523297A (en) * 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5827840A (en) * 1996-08-01 1998-10-27 The Research Foundation Of State University Of New York Promotion of wound healing by chemically-modified tetracyclines
US5789395A (en) * 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
EP2332549A1 (en) * 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Novel tetracyclines and their use in medicine

Similar Documents

Publication Publication Date Title
AU2002256092C1 (en) Controlled delivery of tetracycline compounds and tetracycline derivatives
AU2007338681B2 (en) Substituted tetracycline compounds for treatment of inflammatory skin disorders
AU2007208214B2 (en) Methods of increasing oral bioavailability of tetracyclines
EP0923378B1 (en) Promotion of wound healing by chemically-modified tetracyclines
ES2258854T3 (es) Uso de derivados de tetraciclina para potenciar la produccion de interleucina 10.
JP2005533110A5 (enExample)
GB1080617A (en) Antibiotic compositions for oral use
CA2383364A1 (en) Methods of preparing substituted tetracyclines with transition metal-based chemistries
PL175957B1 (pl) Sposób wytwarzania nowych 7-podstawionych-9-podstawionych-amino-6-demetylo-6-deoksytetracyklin
CA2440472A1 (en) Methods of treating acne
CA2471943A1 (en) .beta.-amyloid protein production-secretion inhibitors
HRP20240351T1 (hr) Cot modulatori i postupci za njihovu uporabu
JP2007535502A5 (enExample)
AU759372B2 (en) A novel inhibitor of cataract formation
RU2006110936A (ru) Применение тигециклина, в отдельности или в комбинации с рифампином, для лечения остеомиелита и/или септического артрита
BR0014610B1 (pt) composiÇÕes compreendendo uma mistura sinÉrgica de compostos ativos tendo propriedades inseticidas e acaricidas, uso da referida mistura, e processos para controle de pragas animais e de preparo de pesticidas.
TR199901887T2 (xx) Karbapenem bile�i�i, bu bile�i�in kullan�m� ve bu bile�ik i�in ara bile�ik.
EP3545762A3 (en) Formulation and composition for preventing and/or dissolving biofilm on the skin of a domestic animal
EP2250887A3 (en) Use of non-antibacterial tetracycline analog CMT-1002 and formulations thereof for the treatment of bacterial exotoxins
MXPA06010404A (es) Metodo para tratar la estenosis aortica con formulaciones de tetraciclina no anti-bacterianas.
NZ538198A (en) Method for reducing C-reactive protein (CRP) levels by administering a non-antibacterial tetracycline formulation or a low dose of an antibacterial tetracycline formulation
Krout et al. Tetracyclines: history and current formulation review from a dermatology perspective
SERGEANT et al. Effect of antibacterial agents on clean wounds
Kalvit et al. 32 Newer Tetracyclines—Eravacycline and Omadacycline
IL312857A (en) Synthetic cannabinoid compounds, pharmaceutical compositions, and treatment methods